Therapeutic human anti-IL-1R1 monoclonal antibody
View Patent ↗Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.
1. An isolated nucleic acid molecule comprising:
(a) nucleotide sequences encoding human heavy chain framework regions, a nucleotide sequence encoding a human heavy chain CDR1 region comprising SEQ ID NO: 61, a nucleotide sequence encoding a human heavy chain CDR2 region comprising SEQ ID NO: 64, and a nucleotide sequence encoding a human heavy chain CDR3 region comprising SEQ ID NO: 67; and nucleotide sequences encoding human light chain framework regions, a nucleotide sequence encoding a human light chain CDR1 region comprising SEQ ID NO: 70, a nucleotide sequence encoding a human light chain CDR2 region comprising SEQ ID NO: 72, and a nucleotide sequence encoding a human light chain CDR3 region comprising SEQ ID NO: 74; or
(b) nucleotide sequences encoding human heavy chain framework regions, a nucleotide sequence encoding a human heavy chain CDR1 region comprising SEQ ID NO: 62, a nucleotide sequence encoding a human heavy chain CDR2 region comprising SEQ ID NO: 65, and a nucleotide sequence encoding a human heavy chain CDR3 region comprising SEQ ID NO: 68; and nucleotide sequences encoding human light chain framework regions, a nucleotide sequence encoding a human light chain CDR1 region comprising SEQ ID NO: 70, a nucleotide sequence encoding a human light chain CDR2 region comprising SEQ ID NO: 72, and a nucleotide sequence encoding a human light chain CDR3 region comprising SEQ ID NO: 74.
2. The isolated nucleic acid molecule of claim 1 , wherein the isolated nucleic acid molecule comprises a combination of nucleic acid sequences that encode a heavy chain variable region and a light chain variable region of an antibody that specifically binds IL-1R1, wherein the combination comprises:
(a) SEQ ID NO: 89 and SEQ ID NO: 88; or
(b) SEQ ID NO: 87 and SEQ ID NO: 88.
3. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a human antibody that specifically binds IL-1R1, wherein the antibody comprises:
(a) a heavy chain having a heavy chain variable region, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 89, and wherein the antigen-binding fragment comprises an N-terminal or C-terminal deletion of the amino acid sequence encoded by SEQ ID NO: 89, wherein the N-terminal or C-terminal deletion comprises SEQ ID NO: 61, SEQ ID NO: 64, and SEQ ID NO: 67; or
(b) a heavy chain having a heavy chain variable region, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 87, and wherein the antigen-binding fragment comprises an N-terminal or C-terminal deletion of the amino acid sequence encoded by SEQ ID NO: 87, wherein the N-terminal or C-terminal deletion comprises SEQ ID NO: 62, SEQ ID NO: 65, and SEQ ID NO: 68.
4. An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a human antibody that specifically binds IL-1R1, wherein the antibody comprises:
(a) a heavy chain having a heavy chain variable region, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 89, and wherein the antigen-binding fragment comprises SEQ ID NO: 61, SEQ ID NO: 64, and SEQ ID NO: 67, and wherein the antibody comprises a light chain having a light chain variable region, or an antigen-binding fragment thereof, wherein the light chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 88, and wherein the antigen-binding fragment comprises SEQ ID NO: 70, SEQ ID NO: 72, and SEQ ID NO: 74; or
(b) a heavy chain having a heavy chain variable region, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 87, and wherein the antigen-binding fragment comprises SEQ ID NO: 62, SEQ ID NO: 65, and SEQ ID NO: 68, and wherein the antibody comprises a light chain having a light chain variable region, or an antigen-binding fragment thereof, wherein the light chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 88, and wherein the antigen-binding fragment comprises SEQ ID NO: 70, SEQ ID NO: 72, and SEQ ID NO: 74.
5. The isolated nucleic acid molecule of claim 1 or 4 wherein the nucleic acid molecule encodes an antibody that is an IgG2 antibody.
6. The isolated nucleic acid molecule of claim 1 or 4 , wherein the nucleic acid molecule encodes an antibody that is a fully human antibody.
7. A vector comprising the nucleic acid molecule of any of claim 1 or 4 .
8. A vector comprising the nucleic acid molecule of claim 5 .
9. A vector comprising the nucleic acid molecule of claim 6 .
10. An expression vector comprising the nucleic acid molecule of any of claim 1 or 4 .
11. An expression vector comprising the nucleic acid molecule of claim 5 .
12. An expression vector comprising the nucleic acid molecule of claim 6 .
13. An isolated host cell comprising the vector of claim 7 .
14. An isolated host cell comprising the expression vector of claim 10 .
15. The host cell of claim 13 that is a eukaryotic cell.
16. The host cell of claim 14 that is a eukaryotic cell.
17. A set of nucleic acid molecules comprising:
(a) a first nucleic acid molecule encoding human heavy chain framework regions, a nucleotide sequence encoding a human heavy chain CDR1 region comprising SEQ ID NO: 61, a nucleotide sequence encoding a human heavy chain CDR2 region comprising SEQ ID NO: 64, and a nucleotide sequence encoding a human heavy chain CDR3 region comprising SEQ ID NO: 67; and a second nucleic acid molecule encoding human light chain framework regions, a nucleotide sequence encoding a human light chain CDR1 region comprising SEQ ID NO: 70, a nucleotide sequence encoding a human light chain CDR2 region comprising SEQ ID NO: 72, and a nucleotide sequence encoding a human light chain CDR3 region comprising SEQ ID NO: 74; or
(b) a first nucleic acid molecule encoding human heavy chain framework regions, a nucleotide sequence encoding a human heavy chain CDR1 region comprising SEQ ID NO: 62, a nucleotide sequence encoding a human heavy chain CDR2 region comprising SEQ ID NO: 65, and a nucleotide sequence encoding a human heavy chain CDR3 region comprising SEQ ID NO: 68; and a second nucleic acid molecule encoding human light chain framework regions, a nucleotide sequence encoding a human light chain CDR1 region comprising SEQ ID NO: 70, a nucleotide sequence encoding a human light chain CDR2 region comprising SEQ ID NO: 72, and a nucleotide sequence encoding a human light chain CDR3 region comprising SEQ ID NO: 74.
18. The set of nucleic acid molecules of claim 17 , wherein:
(a) the first nucleic acid molecule comprises SEQ ID NO: 89 and the second nucleic acid molecule comprises SEQ ID NO: 88; or
(b) the first nucleic acid molecule comprises SEQ ID NO: 87 and the second nucleic acid molecule comprises SEQ ID NO: 88.
19. A set of nucleic acid molecules comprising nucleotide sequences that encode a human antibody that specifically binds IL-1R1, comprising:
(a) a first nucleic acid molecule encoding a human antibody heavy chain having a heavy chain variable region, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 9, and wherein the antigen-binding fragment comprises an N-terminal or C-terminal deletion of the amino acid sequence encoded by SEQ ID NO: 9, wherein the N-terminal or C-terminal deletion comprises SEQ ID NO: 61, SEQ ID NO: 64, and SEQ ID NO: 67; and a second nucleic acid molecule encoding a human antibody light chain; or
(b) a first nucleic acid molecule encoding a human antibody heavy chain having a heavy chain variable region, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 13, and wherein the antigen-binding fragment comprises an N-terminal or C-terminal deletion of the amino acid sequence encoded by SEQ ID NO: 13, wherein the N-terminal or C-terminal deletion comprises SEQ ID NO: 62, SEQ ID NO: 65, and SEQ ID NO: 68; and a second nucleic acid molecule encoding a human antibody light chain.
20. A set of nucleic acid molecules comprising:
(a) a first nucleic acid molecule encoding a human antibody heavy chain having a heavy chain variable region, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 89, and wherein the antigen-binding fragment comprises SEQ ID NO: 61, SEQ ID NO: 64, and SEQ ID NO: 67; and a second nucleic acid molecule encoding a human antibody light chain having a light chain variable region, or an antigen-binding fragment thereof, wherein the light chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 88, and wherein the antigen-binding fragment comprises SEQ ID NO: 70, SEQ ID NO: 72, and SEQ ID NO: 74; or
(b) a first nucleic acid molecule encoding a human antibody heavy chain having a heavy chain variable region, or an antigen-binding fragment thereof, wherein the heavy chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 87, and wherein the antigen-binding fragment comprises SEQ ID NO: 62, SEQ ID NO: 65, and SEQ ID NO: 68; and a second nucleic acid molecule encoding a human antibody light chain having a light chain variable region, or an antigen-binding fragment thereof, wherein the light chain variable region comprises the amino acid sequence encoded by SEQ ID NO: 88, and wherein the antigen-binding fragment comprises SEQ ID NO: 70, SEQ ID NO: 72, and SEQ ID NO: 74.
21. A set of nucleic acid molecules comprising:
(a) a first nucleic acid molecule comprising SEQ ID NO: 89; and a second nucleic acid molecule comprising SEQ ID NO: 88; or
(b) a first nucleic acid molecule comprising SEQ ID NO: 87; and a second nucleic acid molecule comprising SEQ ID NO: 88.
22. A set of vectors comprising the nucleic acid molecules of any of claim 17 , 19 , 20 , or 21 , wherein one vector comprises the first nucleic acid molecule and the other vector comprises the second nucleic acid molecule.
23. An isolated host cell comprising the set of vectors of claim 22 .
24. The host cell of claim 23 that is a eukaryotic cell.